L · 0QLQ.L
Ypsomed Holding AG
- Sector
- Healthcare · Medical - Equipment & Services
- Headquarters
- Burgdorf 3401
- Website
- ypsomed.com
Price · as of 2025-03-31
$271.11
Market cap 3.73B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $211.20 | -22.1% |
| Intrinsic Value(DCF) | $32,760.68 | +11,983.99% |
| Graham-Dodd Method(GD) | $48.40 | -82.15% |
| Graham Formula(GF) | $258.30 | -4.72% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $41.60 | $1.40 | |||
| 2012 | $16.40 | $6.70 | |||
| 2013 | $13.90 | $0.80 | |||
| 2014 | $19.10 | $20.70 | |||
| 2015 | $20.80 | $26.80 | |||
| 2016 | $24.70 | $46.40 | |||
| 2017 | $25.50 | $79.00 | |||
| 2018 | $128.14 | $102.41 | $335.28 | $26.40 | $103.90 |
| 2019 | $117.23 | $81.59 | $80.35 | $30.70 | $25.20 |
| 2020 | $129.35 | $78.89 | $8.54 | $24.40 | $0.00 |
| 2021 | $147.74 | $80.07 | $9.01 | $28.50 | $4.50 |
| 2022 | $132.82 | $76.21 | $8.54 | $21.20 | $38.60 |
| 2023 | $251.27 | $133.90 | $9.45 | $48.40 | $52.90 |
| 2024 | $392.54 | $190.15 | $21.42 | $50.90 | $95.90 |
| 2025 | $413.31 | $226.03 | $462.82 | $48.40 | $258.30 |
AI valuation
Our deep-learning model estimates Ypsomed Holding AG's (0QLQ.L) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $211.20
- Current price
- $271.11
- AI upside
- -22.1%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$32,760.68
+11,983.99% upside
Graham-Dodd
$48.40
-82.15% upside
Graham Formula
$258.30
-4.72% upside
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
- CEO
- Simon Michel
- Employees
- 2.6K
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($32,760.68 ÷ $271.11) − 1 = +11,983.99% (DCF, example).